portal-innovations-logo-1 (1)-1

***WE ARE AT CAPACITY FOR THE EVENT AND REGISTRATION IS NOW CLOSED***

 

Rising Stars in Oncology with Portal Innovations

Join Portal Innovations on April 25th for lunch and a panel discussion with rising stars in Oncology. The annual American Association for Cancer Research (AACR) conference will be taking place during this time, and we'd love to host attendees at the Portal space. 

  • Date: Friday, April 25, 2025 | Time: 11:30 AM – 2:00 PM
  • Location: Portal Innovations - 400 N Aberdeen, Chicago, IL

Program Overview:

 11:30 AM – Lunch & Networking: Welcome lunch with light bites and drinks, while offering a space to settle in and network before heading to AACR.

12:30 PM – Opening Remarks & Founder Spotlights: Welcome & Introduction: Ritu Shah, Managing Director, Portal Innovations Portal’s national reach and the future of oncology innovation. Our Founder Spotlight will feature Rising Stars in Oncology, followed by a Q&A.

  • Iterion Therapeutics: Developing therapeutics for cancer, focusing on tegavivint—a small molecule inhibitor of TBL1 that targets the Wnt/beta-catenin pathway.
  • OncoSpherix: Developing small-molecule therapeutics for cancers resistant to current treatments, targeting hypoxic regions in tumors.
  • CrossBridge Bio: Innovating Antibody-Drug Conjugates (ADCs) through stable dual linker payload technology to deliver improved therapeutics for patients.
  • ReAx Biotechnologies: A chemoproteomics drug discovery company delivering first-in-class therapies for challenging protein targets using an innovative platform.
  • Grove BioPharma: Advancing Precision-Linked Proteomimetics™ (PLPs), a novel class of synthetic biologics targeting intracellular protein-protein interactions.
  • SIWA Therapeutics: Targeting both tumor and senescent cells with its proprietary humanized monoclonal antibody, SIWA318H. In preclinical models, SIWA318H has shown significant tumor reduction, complete remission in pancreatic cancer, and promising results against lung metastases, supporting its potential as a comprehensive immunotherapy for multiple cancer types.
  • ARTIDIS: Pioneering a nanomechanical analysis platform that enables rapid cancer diagnosis and personalized treatment strategies. By integrating a proprietary nanomechanical biomarker with patient clinical data, ARTIDIS offers real-time insights into tumor aggressiveness and metastasis risk, helping clinicians deliver the right treatment the first time.

 1:00 PM – Open Networking & Dessert: Connect with the founders, peers, and partners

Screenshot 2025-04-16 at 2.19.35 PM
DSC_0378

Thanks to our sponsor!

cradl-logo-vertical

Register here!